Présentation de l'entreprise
Novo Nordisk A/S is a global leader engaged in the research, development, manufacture, and distribution of pharmaceutical products, operating specifically within the Obesity and Diabetes Care segments as well as Rare Disease. The company functions within the Healthcare sector and the Drug Manufacturers - General industry, positioning itself as a critical provider of essential therapeutic solutions for metabolic and rare conditions. With a substantial market capitalization of $163.82B, an annual revenue of $309.06B, and an employee base of 68,794, the entity demonstrates significant operational scale. These valuation and revenue figures indicate that Novo Nordisk A/S commands a dominant position in its respective markets, reflecting the high demand for its specialized pharmaceutical offerings and its capacity to generate revenue at a massive level relative to its sector peers.
Santé financière
The company reported a revenue of $309.06B, a net income of $102.43B, and an EBITDA of $153.29B over the trailing twelve months. The substantial gap between the total revenue figure and the net income reveals a highly efficient cost structure, where operating expenses and taxes consume approximately 66.9% of top-line sales, resulting in a profit margin of 33.1%. Novo Nordisk A/S generated a free cash flow of $376.88M, which provides the organization with significant financial flexibility to fund ongoing research and development initiatives or return capital to shareholders. The company maintains a gross margin of 82.4%, indicating strong pricing power and high-value product mixes, while the operating margin stands at 44.5%, reflecting effective control over operating costs. Regarding liquidity and leverage, the firm holds $26.96B in cash against $130.96B in debt, resulting in a debt-to-equity ratio of 67.49. The current ratio is recorded at 0.80, which indicates that the company's current assets are insufficient to cover its current liabilities without relying on external financing or asset sales. Furthermore, the Return on Equity reaches 60.7% and the Return on Assets is 17.4%, metrics that reveal exceptional management effectiveness in deploying capital to generate returns relative to the equity base and total asset utilization.
Évaluation de la valorisation
The stock trades with a P/E Ratio (TTM) of 10.40 and a Forward P/E of 10.83, suggesting that the market expects a modest increase in earnings as the forward multiple is slightly higher than the trailing multiple. The Price to Book ratio is 5.49, indicating that the market values the company's equity at a significant premium over its accounting book value, likely due to the high intangible value of its intellectual property and brand. Alternative valuation metrics such as a Price to Sales of 0.53 and an EV/EBITDA of 1.75 suggest a valuation structure that appears compressed relative to the company's massive earnings power and revenue base. In terms of trading range, the 52-Week High is $81.44 and the 52-Week Low is $35.12; without a specific current price provided in the data, the relative position cannot be precisely calculated, but the wide range implies significant volatility in recent trading periods. The Beta value of 0.27 indicates that the stock exhibits very low price volatility relative to the broader market, moving in a much less sensitive manner than the S&P 500.
Growth & Income
Revenue Growth (YoY) is recorded at -7.6% while Earnings Growth (YoY) is -4.7%, implying that earnings are declining at a slower rate than revenue, which may suggest improving operational efficiency or cost containment strategies despite shrinking top-line sales. The company offers a Dividend Yield of 4.9% with a Payout Ratio of 50.4%, indicating that the dividend is funded by nearly half of the reported earnings, a ratio that must be monitored given the negative growth rates to ensure sustainability. The negative growth figures suggest a contraction phase in the current business cycle or market environment, where the company is prioritizing profitability preservation over expansion. Overall, the growth and income profile presents a scenario of a mature, high-dividend yielding company currently navigating a period of revenue contraction while maintaining robust profitability margins and a conservative dividend payout strategy.